Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
Carfilzomib (Kyprolis®, Amgen), a second-generation proteasome inhibitor, is capable of covalent bonding and irreversible inhibition of the 20S proteasome chymotrypsin-like activity. In 2016 this drug was approved in Russia for monotherapy of relapsed refractory multiple myeloma (MM) and in combinat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2018-12-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2018/12/3-1.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|